title: Genetic analysis of early- versus late-stage ovarian tumors.
abstract: In the United States, ovarian cancer is the fourth most common cause of cancer-related deaths among women. The most important prognostic factor for this cancer is tumor stage, or extent of disease at diagnosis. Although women with low-stage tumors have a relatively good prognosis, most women diagnosed with late-stage disease eventually succumb to their cancer. In an attempt to understand early events in ovarian carcinogenesis, and to explore steps in its progression, we have applied multiple molecular genetic techniques to the analysis of 21 early-stage (stage I/II) and 17 advanced-stage (stage III/IV) ovarian tumors. These techniques included expression profiling with cDNA microarrays containing approximately 18,000 expressed sequences, and comparative genomic hybridization to address the chromosomal locations of copy number gains as well as losses. Results from the analysis indicate that early-stage ovarian cancers exhibit profound alterations in gene expression, many of which are similar to those identified in late-stage tumors. However, differences observed at the genomic level suggest differences between the early- and late-stage tumors and provide support for a progression model for ovarian cancer development.
authors.affiliation: Department of Experimental Pathology, Division of Laboratory Medicine, The Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA.
authors.forename: V
authors.initials: V
authors.lastname: Shridhar
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: A
authors.initials: A
authors.lastname: Pandita
authors.forename: S
authors.initials: S
authors.lastname: Iturria
authors.forename: R
authors.initials: R
authors.lastname: Avula
authors.forename: J
authors.initials: J
authors.lastname: Staub
authors.forename: M
authors.initials: M
authors.lastname: Morrissey
authors.forename: E
authors.initials: E
authors.lastname: Calhoun
authors.forename: A
authors.initials: A
authors.lastname: Sen
authors.forename: K
authors.initials: K
authors.lastname: Kalli
authors.forename: G
authors.initials: G
authors.lastname: Keeney
authors.forename: P
authors.initials: P
authors.lastname: Roche
authors.forename: W
authors.initials: W
authors.lastname: Cliby
authors.forename: K
authors.initials: K
authors.lastname: Lu
authors.forename: R
authors.initials: R
authors.lastname: Schmandt
authors.forename: G B
authors.initials: GB
authors.lastname: Mills
authors.forename: R C
authors.initials: RC
authors.lastname: Bast
authors.forename: C D
authors.initials: CD
authors.lastname: James
authors.forename: F J
authors.initials: FJ
authors.lastname: Couch
authors.forename: L C
authors.initials: LC
authors.lastname: Hartmann
authors.forename: J
authors.initials: J
authors.lastname: Lillie
authors.forename: D I
authors.initials: DI
authors.lastname: Smith
mesh_terms: D018450:Disease Progression; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D015894:Genome, Human; D006801:Humans; D009367:Neoplasm Staging; D009693:Nucleic Acid Hybridization; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured